Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.11 EUR | -1.86% | -9.44% | -19.47% |
Apr. 15 | Sanofi: progress in hematology trial | CF |
Apr. 15 | Innate Pharma: progress in hematology trial | CF |
Business Summary
- revenues from collaboration and licensing agreements (84.2%);
- government financing for research expenditure (15.8%).
At the end of 2023, the company had a portfolio of 7 products in clinical development, including 1 in phase III (Monalizumab for the treatment of cancer), 2 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphomas and IPH5201 for the treatment of cancer) and 4 in phase I (IPH5301 for the treatment of solid tumours, IPH6101 for the treatment of relapsed or refractory acute myeloid leukaemia, IPH6401 for the treatment of multiple myeloma and IPH6501 for the treatment of non-Hodgkin lymphoma).
Number of employees: 179
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development of Pharmaceutical Products
100.0
%
| 58 | 100.0 % | 62 | 100.0 % | +6.88% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 58 | 100.0 % | 62 | 100.0 % | +6.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Eric Vivier
FOU | Founder | 60 | 99-09-22 |
Chief Executive Officer | 62 | 99-09-22 | |
Frederic Lombard
DFI | Director of Finance/CFO | 49 | 21-03-31 |
Sonia Quaratino
CTO | Chief Tech/Sci/R&D Officer | - | Oct. 31 |
Odile Belzunce
CMP | Compliance Officer | 44 | 05-01-31 |
Yannis Morel
COO | Chief Operating Officer | 50 | 01-11-30 |
Henry Wheeler
IRC | Investor Relations Contact | 40 | 21-05-31 |
General Counsel | 51 | 20-09-30 | |
Corporate Officer/Principal | 54 | 21-12-31 | |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 99-09-22 | |
Gilles Brisson
BRD | Director/Board Member | 72 | 07-06-25 |
Olivier Martinez
BRD | Director/Board Member | 54 | 10-05-24 |
Sally Bennett
BRD | Director/Board Member | 52 | 22-05-19 |
Chairman | 63 | 09-06-22 | |
Pascale Boissel
BRD | Director/Board Member | 57 | 20-05-18 |
Director/Board Member | 62 | 15-04-26 | |
Jean-Yves Blay
BRD | Director/Board Member | 61 | 17-12-12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 6,509 | 0 | 0 | 75.30 % |
Stock B | 1 | 80,860,563 | 60,887,105 ( 75.30 %) | 18,575 ( 0.0230 %) | |
Stock C | 0 | 7,581 | 0 | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
INNATE PHARMA 0.02% | 18,575 | 0.02% | 43,833 $ |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.70% | 185M | |
-1.82% | 41.35B | |
+41.65% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- IPH Stock
- Company Innate Pharma